VivorCare is the first virtual survivorship clinic for those living with and beyond cancer.
Meet Dr. Stephanie Smith, Dr. Lidia Schapira, Elle Billman, and Dr. Natasha Steele – the “dream team” from Stanford Medicine who have created an exciting new resource for cancer survivors. This podcast offers a unique opportunity to hear directly from both survivors and experts in survivorship care on a wide range of subjects. It is informative, engaging, and just what we need to feel less alone in our struggles.
This article in HemOnc Today describes a recent study that evaluated the use of specific biomarkers, namely global longitudinal strain (GLS) and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) to identify childhood cancer survivors who may be at risk for cardiomyopathy. The study was done through the St. Jude Lifetime Cohort study.
Almost all cancer survivors have a few things in common: shock at being diagnosed, significant challenges in dealing with the side effects of treatment, and anxiety or worry when active treatment ends and the oncologist’s office says, “We’ll see you in three months.”
Being diagnosed with cancer at any age puts many in a tailspin.
Dr. Stacy Wentworth is a radiation oncology specialist in Greensboro, North Carolina, and an Assistant Professor of Radiation Oncology at Wake Forest School of Medicine.
When thinking about cancer research, many people think of studies focused on evaluating new or better ways to treat the cancer itself. What may not come to mind is a type of research known as “survivorship research.”
During this special patient webinar, you will learn critical insights about new advances in minimally-invasive, robotic heart valve surgery. The featured speakers are Dr. Pavan Atluri, Director of Minimally Invasive and Robotic Cardiac Surgery, and Dr. Michael Ibrahim, Director of Reconstructive Valve Surgery, at Penn Medicine.
In the first episode of The HemOnc Pulse in 2024, the lead researchers of the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) consortium discuss the immense labor and fortitude it took to successfully launch the consortium, which includes a global team of diverse experts focused on the prognosis, epidemiology, treatment, survivorship, and health outcomes in patients with Hodgkin lymphoma.